Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
The source uses indexed renal thresholds but prints an unindexed Cockcroft-Gault formula; preserve the distinction rather than silently treating the units as equivalent.
Check source scope before reading a dose
GlobalRPh RX List - INVANZ
Product / population
Adult parenteral ertapenem; selected label renal/HD instructions. Pediatric renal doses are not established here.
Renal method
Source prints CrCl mL/min/1.73 m2 but supplies unindexed Cockcroft-Gault formula; reconcile method.
Source revision
Source revision date not established in selected retrieval.
Retrieved
2026-09-07
Local review status
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
Daily label regimen versus case-by-case post-HD institutional dosing
The label mirror uses a daily renal regimen with a timing-dependent post-HD supplement. UCSF also offers a selected post-HD-only strategy, with toxicity, age and low-weight qualifications. The source renal units and exactly-30 boundary do not align automatically.
What to reconcile: Use one complete protocol with the dialysis prescription and ID/pharmacy review. Do not add the label supplement to an institutional post-HD dose or silently equate indexed and unindexed clearance.
Exactly six hours before HD: overlapping source wording
The label mirror says a supplement is needed within six hours but not needed when the dose is at least six hours before dialysis. The boundary is overlapping as printed.
What to reconcile: Clarify the timing endpoint with the controlling product label and dialysis pharmacist. Do not round an administration time to decide which instruction applies.
GlobalRPh-hosted RX List · Adult parenteral ertapenem; selected label renal/HD instructions. Pediatric renal doses are not established here.
Renal method: Source prints CrCl mL/min/1.73 m2 but supplies unindexed Cockcroft-Gault formula; reconcile method. Source date: Source revision date not established in selected retrieval. Retrieved: 2026-09-07
Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.
Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.
Renal dosing, restrictions and evidence limits
At the source-printed CrCl threshold of 30 mL/min/1.73 m2 or less, adults receive 500 mg daily; above 30 no renal reduction is required. If 500 mg was given within six hours before hemodialysis, give 150 mg afterward. The same source says no supplement when administered at least six hours beforehand, leaving exactly six hours ambiguous. Pediatric renal, peritoneal-dialysis and hemofiltration data are absent. The formula/units mismatch also needs clarification.
RDM43-rxlist-ertapenem-afd03f03bc-C1 · Source locator: Selected Dosage / Renal Impairment / Warnings sections; see source-specific qualifications in this summary.
Source-specific limits
Product page independently located after index-link resolver failure; exact index destination remains unverified.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh v6.6 | RDM66-DIRECT-PHP-20260911 | Local library date 2026-09-11. Selected-card identity does not imply clinical verification.